Article thumbnail

Design, Synthesis and Biological Evaluation of New 5,5-Diarylhydantoin Derivatives as Selective Cyclooxygenase-2 Inhibitors

By Afshin Zarghi, Farin Sattary Javid, Razieh Ghodsi, Orkideh G. Dadrass, Bahram Daraei and Mehdi Hedayati


A new group of 5,5-diarylhydantoin derivatives bearing a methylsulfonyl COX-2 pharmacophore at the para position of the C-5 phenyl ring were designed and synthesized as selective COX-2 inhibitors. In vitro COX-1/COX-2 inhibition structure-activity relationships identified 5-[4-(methylsulfonyl)phenyl]-5-phenyl-hydantoin (4) as a highly potent and selective COX-2 inhibitor (COX-2 IC50 = 0.077 μM; selectivity index > 1298). It was more selective than the reference drug celecoxib (COX-2 IC50 = 0.060 μM; selectivity index = 405). A molecular modeling study where 4 was docked in the binding site of COX-2 indicated that the p-MeSO2 COX-2 pharmacophore group on the C-5 phenyl ring is oriented in the vicinity of the COX-2 secondary pocket. The results of this study showed that the type of substituent on the N-3 hydantoin ring substituent is important for COX-2 inhibitory activity

Topics: Research Article
Publisher: Österreichische Apotheker-Verlagsgesellschaft
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1998). 2. Ann Rev Pharmacol Toxicol.
  2. (1998). Anti-inflammatory drugs and their mechanism of action. Inflamm Res.
  3. (2003). Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J Neurol.
  4. (1998). Automated docking using a lamarkian genetic algorithm and an empirical binding free energy function.
  5. (2008). Breast cancer and use of nonsteroidal anti-inflammatory drugs: A metaanalysis.
  6. (1998). Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res.
  7. (2006). Coxibs and cardiovascular side effects: From ligh to shadow. Curr Pharm Des.
  8. (2001). Discovery and design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic, anti-inflammatory drugs with potential utility as anti-cancer agents. Current Drug Targets.
  9. (2003). Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res.
  10. (1991). Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing.
  11. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol.
  12. (2004). Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.
  13. (2007). Nonsteroidal anti-inflammatory drugs and risk of lung cancer.
  14. (2004). One-pot synthesis of phenytoin analogs.
  15. (2006). Rofecoxib increases susceptibity of human LDL and membrane lipids to oxidative damage: A mechanism of cardiotoxicity. J Cardivasc Pharmacol.
  16. (1996). Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.
  17. (1995). Syntheses of substituted oxazolo -1,3,4-thiadiazoles, 1,3,4- oxadiazoles and 1,2,4-triazoles. J Heterocycl Chem.
  18. (2004). Synthesis and biological evaluation of 2,3-diarylpyrazines and quinoxalines as selective COX-2 inhibitors. Bioorg Med Chem.
  19. (1997). Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC58635, celecoxib). J Med Chem.
  20. (2007). Synthesis of 2,3-diaryl-1,3-thiazolidine-4-one derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett.
  21. (2006). synthesis, and biological evaluation of 1,3-diarylprop-2-en-1-ones: A novel class of cyclooxygenase-2 inhibitors. Bioorg Med Chem.
  22. (1999). The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett.